• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Sera Prognostics Inc.

    8/5/25 10:22:21 AM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    SERA PROGNOSTICS, INC.

    (Name of Issuer)


    Class A Common Stock $0.0001 par value per share

    (Title of Class of Securities)


    81749D107

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81749D107


    1Names of Reporting Persons

    Aberdeen Group plc
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,227,367.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,227,367.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,227,367.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.07 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    81749D107


    1Names of Reporting Persons

    abrdn Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,227,367.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,227,367.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,227,367.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.07 %
    12Type of Reporting Person (See Instructions)

    CO, IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SERA PROGNOSTICS, INC.
    (b)Address of issuer's principal executive offices:

    2749 E. PARLEYS WAY, SUITE 200, SALT LAKE CITY, UTAH 84109
    Item 2. 
    (a)Name of person filing:

    Aberdeen Group plc abrdn Inc.
    (b)Address or principal business office or, if none, residence:

    Aberdeen Group plc 1 George Street Edinburgh, United Kingdom EH2 2LL abrdn Inc. 1900 Market Street Suite 200. Philadelphia, PA 19103
    (c)Citizenship:

    Aberdeen Group plc - UNITED KINGDOM abrdn Inc. - UNITED STATES
    (d)Title of class of securities:

    Class A Common Stock $0.0001 par value per share
    (e)CUSIP No.:

    81749D107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,227,367
    (b)Percent of class:

    6.07  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Aberdeen Group plc - 0 abrdn Inc. - 0

     (ii) Shared power to vote or to direct the vote:

    Aberdeen Group plc - 2,227,367 abrdn Inc. - 2,227,367

     (iii) Sole power to dispose or to direct the disposition of:

    Aberdeen Group plc - 0 abrdn Inc. - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Aberdeen Group plc - 2,227,367 abrdn Inc. - 2,227,367

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Aberdeen Group plc
     
    Signature:C. Cole
    Name/Title:Chris Cole/ Senior Major Shareholding Reporting Analyst
    Date:08/05/2025
     
    abrdn Inc.
     
    Signature:C.Cole
    Name/Title:Chris Cole/ Senior Major Shareholding Reporting Analyst
    Date:08/05/2025
    Exhibit Information

    Aberdeen Group plc abrdn Holdings Limited abrdn Inc. Aberdeen Group plc is the parent company. abrdn Holdings Limited is the intermediate holding company for abrdn Inc. abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

    Get the next $SERA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Sera Prognostics Inc.

    SCHEDULE 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    8/14/25 6:08:27 PM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form 144 filed by Sera Prognostics Inc.

    144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    8/11/25 4:34:52 PM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Sera Prognostics Inc.

    10-Q - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    8/6/25 4:09:15 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Lindgardt Zhenya sold $21,770 worth of shares (8,571 units at $2.54), decreasing direct ownership by 1% to 832,294 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    8/11/25 4:37:48 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Data Officer Kearney Paul sold $16,408 worth of shares (6,460 units at $2.54), decreasing direct ownership by 3% to 188,940 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    8/11/25 4:37:31 PM ET
    $SERA
    Medical Specialities
    Health Care

    General Counsel Jackson Benjamin sold $16,375 worth of shares (6,447 units at $2.54), decreasing direct ownership by 5% to 127,751 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    8/11/25 4:37:15 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2025 ended June 30, 2025. Second Quarter and Recent Highlights: Ongoing progress in engaging Medicaid plans in targeted states with prior PreTRM clinical study experience. Notable traction in two particular states with above-average premature birth rates, presenting strong commercial o

    8/6/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025

    SALT LAKE CITY, July 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2025 financial results on Wednesday, August 6, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    7/29/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

    SALT LAKE CITY, May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock ConferenceDate: June 3 – 5, 20251X1 Meetings OnlyDoug Fisher, M.D., Strategic Advisor to Sera and former Chief Business Officer, will participate in meetings on Wednesday, June 4, 2025. Jefferies

    5/29/25 8:30:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sera Prognostics downgraded by Citigroup with a new price target

    Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

    3/30/22 7:52:32 AM ET
    $SERA
    Medical Specialities
    Health Care

    Oppenheimer initiated coverage on Sera Prognostics with a new price target

    Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

    11/19/21 4:55:47 AM ET
    $SERA
    Medical Specialities
    Health Care

    Cowen resumed coverage on Sera Prognostics

    Cowen resumed coverage of Sera Prognostics with a rating of Outperform

    10/15/21 7:31:16 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/4/24 7:19:49 AM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Sera Prognostics Inc.

    SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    4/1/24 7:33:43 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Financials

    Live finance-specific insights

    View All

    SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2025 ended June 30, 2025. Second Quarter and Recent Highlights: Ongoing progress in engaging Medicaid plans in targeted states with prior PreTRM clinical study experience. Notable traction in two particular states with above-average premature birth rates, presenting strong commercial o

    8/6/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025

    SALT LAKE CITY, July 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2025 financial results on Wednesday, August 6, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    7/29/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

    5/7/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    View All

    SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

    Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

    5/8/25 4:40:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

    SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

    3/19/25 4:10:00 PM ET
    $EXAS
    $QTRX
    $SERA
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

    SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the

    5/15/23 5:15:00 PM ET
    $SERA
    Medical Specialities
    Health Care